The safety of antiangiogenic agents and PARP inhibitors in platinum-sensitive recurrent ovarian cancer
Sign Up to like & getrecommendations! Published in 2017 at "Expert Opinion on Drug Safety"
DOI: 10.1080/14740338.2017.1325871
Abstract: ABSTRACT Introduction: Recurrence is a common event in endothelial ovarian cancer (EOC) patients, and the choice of the most appropriate treatment is driven by the platinum-free interval, molecular characteristics of the disease such as BRCA… read more here.
Keywords: parp inhibitors; agents parp; ovarian cancer; antiangiogenic agents ... See more keywords